Levipil Injection contains Levetiracetam 100mg, an antiepileptic agent indicated for the treatment of partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby stabilizing neuronal activity and preventing seizure propagation. This injectable formulation is intended for intravenous administration when oral therapy is not feasible, ensuring rapid onset of action in acute settings. Levipil Injection is typically used as adjunctive therapy in adults and pediatric patients aged one month and older. The pharmacokinetic profile of Levetiracetam is characterized by rapid absorption, minimal protein binding, and predominant renal excretion, necessitating dose adjustments in renal impairment. Common adverse effects include somnolence, dizziness, headache, and behavioral changes such as irritability or agitation. Caution is advised in patients with a history of psychiatric disorders or suicidal ideation. Levipil Injection should be administered under medical supervision with appropriate monitoring of clinical response and tolerability. It is contraindicated in patients with known hypersensitivity to Levetiracetam or any of the excipients. Proper aseptic technique must be observed during preparation and administration to prevent infections.